Clinical Trials Logo

Kidney Neoplasms clinical trials

View clinical trials related to Kidney Neoplasms.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06145139 Enrolling by invitation - Renal Cancer Clinical Trials

KIDNEY-PAGER: Analysis of Circulating Tumor DNA as a Biomarker in Renal Cancer - an Observational Trial

KIDNEY-PAGER
Start date: June 1, 2023
Phase:
Study type: Observational [Patient Registry]

The overall aim of this observational study is to confirm that circulating tumor DNA (ctDNA) detected in plasma and or urine after intended curative treatment for renal cell carcinoma (RCC) can be applied in clinical practice as a marker of subclinical residual disease and risk of recurrence.

NCT ID: NCT02609269 Enrolling by invitation - Prostate Cancer Clinical Trials

Decipher Genomics Resource for Intelligent Discovery

GRID®
Start date: October 2015
Phase:
Study type: Observational [Patient Registry]

To prospectively evaluate the utility of genomic expression data as a tool to better characterize the tumors of individual patients, and to understand how genomic information from individual patients undergoing routine clinical testing can be used in population-level analysis to improve treatment and outcomes.

NCT ID: NCT02287987 Enrolling by invitation - Nephrectomy Clinical Trials

CLamp vs Off Clamp Kidney During Partial Nephrectomy

CLOCK
Start date: October 2014
Phase: N/A
Study type: Interventional

Prospective, randomized trial comparing surgical, functional and oncological outcomes between clamp and clamp-less robot assisted partial nephrectomy.

NCT ID: NCT01465425 Enrolling by invitation - Clinical trials for Pancreatic Neoplasms

Extracolonic Findings on Computed Tomography (CT) Colonography

ACRIN7151
Start date: September 2011
Phase:
Study type: Observational

The ACRIN 7151 trial will use medical records abstraction data from participants with extracolonic findings (ECFs) reported from the ACRIN 6664 National CT Colonography Trial to: 1) measure incidence of diagnostic imaging, hospitalization, and interventional procedures associated with ECFs reported on computed tomography colonography (CTC), delineated by type of ECF; 2) determine potential predictors of follow-up diagnostic imaging, hospitalization, and interventional procedures, delineated by type of ECF; and 3) evaluate the clinical/pathologic diagnoses associated with indeterminate but potentially significant ECFs. These data can be used to incorporate ECFs into existing models on the cost-effectiveness of CTC in colorectal cancer screening and can potentially be used to develop guidelines for the reporting and management of ECFs.